These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18178949)

  • 1. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin.
    De Somer F; Ceelen W; Delanghe J; De Smet D; Vanackere M; Pattyn P; Mortier E
    Perit Dial Int; 2008; 28(1):61-6. PubMed ID: 18178949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from hyponatremia associated with hyperthermic intraperitoneal chemoperfusion with oxaliplatin.
    Nguyen MK
    Perit Dial Int; 2008; 28(1):32-4. PubMed ID: 18178945
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.
    Ceelen WP; Peeters M; Houtmeyers P; Breusegem C; De Somer F; Pattyn P
    Ann Surg Oncol; 2008 Feb; 15(2):535-41. PubMed ID: 17960463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution.
    Mehta AM; Huitema AD; Burger JW; Brandt-Kerkhof AR; van den Heuvel SF; Verwaal VJ
    Ann Surg Oncol; 2017 Apr; 24(4):990-997. PubMed ID: 27896510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin.
    Ceelen W; De Somer F; Van Nieuwenhove Y; Vande Putte D; Pattyn P
    Eur J Surg Oncol; 2013 Jul; 39(7):754-9. PubMed ID: 22878060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia.
    Chalret du Rieu Q; White-Koning M; Picaud L; Lochon I; Marsili S; Gladieff L; Chatelut E; Ferron G
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):571-82. PubMed ID: 25053386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid correction of severe hyperglycaemia during hyperthermic intraperitoneal chemoperfusion with oxaliplatin.
    Cammu G; De Gendt S; Vandeput D; Foubert L
    Acta Chir Belg; 2009; 109(2):256-9. PubMed ID: 19499696
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
    Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
    J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
    van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
    Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of Hyperthermic Intraperitoneal Chemotherapy Perfusion-Related Hyperglycemia.
    Stewart CL; Gleisner A; Halpern A; Ibrahim-Zada I; Luna RA; Pearlman N; Gajdos C; Edil B; McCarter M
    Ann Surg Oncol; 2018 Mar; 25(3):655-659. PubMed ID: 29204776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
    McConnell YJ; Mack LA; Francis WP; Ho T; Temple WJ
    J Surg Oncol; 2013 May; 107(6):591-6. PubMed ID: 23129533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
    Charrier T; Passot G; Peron J; Maurice C; Gocevska S; Quénet F; Eveno C; Pocard M; Goere D; Elias D; Ortega-Deballon P; Vaudoyer D; Cotte E; Glehen O
    Ann Surg Oncol; 2016 Jul; 23(7):2315-22. PubMed ID: 26920385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophagocytic syndrome: an unusual and underestimated complication of cytoreduction surgery with heated intraperitoneal oxaliplatin.
    Schwarz L; Bridoux V; Veber B; Oksenhendler E; Royon V; Michot F; Tuech JJ
    Ann Surg Oncol; 2013 Nov; 20(12):3919-26. PubMed ID: 23838919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study.
    Facy O; Al Samman S; Magnin G; Ghiringhelli F; Ladoire S; Chauffert B; Rat P; Ortega-Deballon P
    Ann Surg; 2012 Dec; 256(6):1084-8. PubMed ID: 22634898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.
    Elias D; Pocard M; Goere D
    Cancer Treat Res; 2007; 134():303-18. PubMed ID: 17633062
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
    Hompes D; D'Hoore A; Wolthuis A; Fieuws S; Mirck B; Bruin S; Verwaal V
    J Surg Oncol; 2014 May; 109(6):527-32. PubMed ID: 24375059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preliminary experience with hyperthermic intraperitoneal chemo-perfusion with oxaliplatin for the treatment of peritoneal carcinomatosis due to colorectal carcinoma].
    Mura G; Framarini M; Vagliasindi A; Cavaliere D; Tauceri F; Solfrini G; Milandria C; Verdecchia GM
    Chir Ital; 2007; 59(2):217-23. PubMed ID: 17500178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion.
    Mahteme H; Wallin I; Glimelius B; Påhlman L; Ehrsson H
    Eur J Clin Pharmacol; 2008 Sep; 64(9):907-11. PubMed ID: 18563401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of heated intraperitoneal oxaliplatin.
    Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.